Indivior Pharmaceuticals, Inc 6-K, filed Dec 20, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-12-20
For: 2023-12-20
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on December 20, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: December 20, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: December 20,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
|
Exhibit
99.1
|
Indivior Settles Patent Dispute with Teva Subsidiary
Actavis
Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC
(LSE/NASDAQ: INDV), a leading
addiction treatment company, today announced that its subsidiaries
Indivior Inc. and Indivior UK Limited (together, "Indivior")
entered into a settlement agreement with Actavis Laboratories UT,
Inc. ("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve
patent disputes regarding Actavis's Abbreviated New Drug
Application ("ANDA") for generic buprenorphine and naloxone
sublingual film. Under the agreement, Indivior granted Actavis a
license to U.S. Patent No. 11,135,216 that would enable Actavis to
launch the generic film products identified in its ANDA in the
United States no earlier than January 31, 2025, unless the
unexpired patent claims are found invalid or unenforceable before
that time in a final judicial decision.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more than
1,000 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Media
Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors
and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-